Key Takeaways:
(Bloomberg) -- uniQure N.V. (NASDAQ: QURE) shares fell 4% after national shareholder rights law firm Hagens Berman announced an update to its investigation into the company, citing recent rebukes from the Food and Drug Administration (FDA) and allegations of distorted clinical data.
The law firm is investigating claims that uniQure may have misled investors about the integrity of its clinical trial data. "We are focused on investors' losses and the allegations that uniQure may have distorted its clinical data," said Reed Kathrein, the Hagens Berman partner leading the investigation. The firm reminded investors of an April 13, 2026, lead plaintiff deadline in the pending securities fraud lawsuit.
The investigation follows a series of extraordinary rebukes by FDA officials regarding the company's data. These rebukes have raised concerns among investors about the viability of uniQure's product pipeline and the potential for regulatory penalties. The allegations of data distortion could jeopardize future product approvals and expose the company to significant litigation costs.
This news is highly likely to negatively impact uniQure's stock price due to increased investor uncertainty. The decline puts the stock at its lowest since the initial FDA announcement. Investors will be closely watching for further updates from the FDA and the outcome of the pending lawsuit.
This article is for informational purposes only and does not constitute investment advice.
